PEDIATRICS Vol. 95 No. 4 April 1995, pp. 598-602
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reappraisal of Lytic Cocktail/Demerol, Phenergan, and Thorazine (DPT) for the Sedation of Children

Committee on Drugs

The DPT lytic cocktail remains a widely used sedative and analgesic for pediatric patients. Neither the combination itself nor its dosage is based on sound pharmacologic data. There is a high rate of therapeutic failure as well as a high rate of serious adverse reactions, including respiratory depression and death, associated with its use.

Even when it is effective, DPT appears to lack many of the desirable characteristics of a sedative for children. Specifically, the dose cannot be titrated easily and individually, the onset of action is significantly delayed (20 to 30 minutes), the duration of sedation is protracted (5 to 20 hours), the duration of analgesia is much shorter (1 to 3 hours), and no anxiolytic or amnestic properties exist.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Statement of retirement:

AAP Publications Retired and Reaffirmed

Pediatrics 115: 1438-1438. [Full Text]



This article has been cited by other articles:


Home page
 NEJMHome page
P. R. Starke, J. Weaver, and B. A. Chowdhury
Boxed Warning Added to Promethazine Labeling for Pediatric Use
N. Engl. J. Med., June 23, 2005; 352(25): 2653 - 2653.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
S. M. Auden, W. L. Sobczyk, R. E. Solinger, and L. J. Goldsmith
Oral Ketamine/Midazolam Is Superior to Intramuscular Meperidine, Promethazine, and Chlorpromazine for Pediatric Cardiac Catheterization
Anesth. Analg., February 1, 2000; 90(2): 299 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
G R Lawson; and R J BRAY
Controversy: Sedation of children for magnetic resonance imaging
Arch. Dis. Child., February 1, 2000; 82(2): 150 - 153.
[Full Text]

Home page
 PediatricsHome page
R. I. Parker, R. A. Mahan, D. Giugliano, and M. M. Parker
Efficacy and Safety of Intravenous Midazolam and Ketamine as Sedation for Therapeutic and Diagnostic Procedures in Children
Pediatrics, March 1, 1997; 99(3): 427 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
E. M. Petrack, C. M. Marx, and M. S. Wright
Intramuscular Ketamine Is Superior to Meperidine, Promethazine, and Chlorpromazine for Pediatric Emergency Department Sedation
Arch Pediatr Adolesc Med, July 1, 1996; 150(7): 676 - 681.
[Abstract] [PDF]